This stabilisation undermines the efficacy of PD-L1-targeted immunotherapy and exacerbates the immunosuppressive microenvironment in pancreatic cancer, while targeting NEK2 can enhance anti-pancreatic cancer immune responses [66]. Here, NEK2 is linked to familial pancreatic carcinoma.